WHO Reports 1,460 Confirmed Bundibugyo Ebola Cases in Congo as Uganda and France Record Linked Cases
The World Health Organization reported continued cross-border transmission of Bundibugyo virus disease on July 3, 2026, with 1,460 confirmed cases and 452 deaths recorded in the Democratic Republic of the Congo as of July 1. Uganda reported 20 confirmed cases and two deaths as of July 2, along with one probable fatal case.
France has also reported a case linked to the outbreak. French authorities notified WHO on June 24 of a laboratory-confirmed imported case. The WHO update does not provide a newer cumulative total for France or indicate that the country has sustained local transmission.
WHO said the transmission in Uganda was epidemiologically linked to the Democratic Republic of the Congo. Its update also documented sustained transmission and secondary transmission among contacts and health workers, making the outbreak a continuing international public-health concern rather than an isolated cluster.
What the reported figures show
The Congo remains the center of the outbreak by reported case and death totals. The 1,460 confirmed cases and 452 deaths are figures for the Democratic Republic of the Congo as of July 1, not a combined total for all affected countries.
Uganda’s figures were reported one day later. They include 20 confirmed cases and two deaths, plus one probable fatal case. A probable case is not the same as a laboratory-confirmed case, so the figures should not be combined as though every suspected or probable infection had been confirmed.
The French case is described as imported. That distinction matters: the notification shows that a case reached France from outside the country, but it does not establish sustained transmission there. WHO’s July 3 update also does not state a broader French case total.
Vaccines remain an open question
The outbreak is also testing the limits of available Ebola countermeasures. WHO technical advisers reviewed Bundibugyo virus disease vaccine candidates at a meeting whose report was published May 28. The candidates included BDBV-specific products from IAVI and Oxford, as well as evidence involving existing Ebola vaccine platforms.
The advisory group recommended prioritizing Bundibugyo-specific candidates and considering studies during outbreaks. That is a research and response recommendation, not a finding that an effective, licensed Bundibugyo-specific vaccine is already available.
WHO separately issued emergency guidance on May 28 about the possible use of Ervebo, an existing Ebola vaccine. The guidance states that Ervebo is licensed for Ebola virus disease caused by Ebola virus, not specifically for Bundibugyo virus disease. WHO reviewed whether the vaccine might provide cross-protection, but the effectiveness of existing Ebola vaccines against Bundibugyo virus remains an evidence question rather than an established clinical conclusion.
What happens next
WHO’s emergency guidance continues to emphasize surveillance, contact tracing, clinical care, infection prevention and community engagement. Those measures are intended to identify infections, limit transmission and protect people who may be exposed, including contacts and health workers.
The agency is also calling for accelerated development of Bundibugyo-specific or broadly protective filovirus vaccines. The technical advisory process points toward outbreak studies and further evaluation of candidate vaccines, while health authorities continue responding to transmission in the Democratic Republic of the Congo and Uganda.
For now, the key development is the outbreak’s geographic reach and sustained transmission across more than one country. The confirmed French case demonstrates international spread, but the available WHO update does not show that France has become a site of sustained transmission. The vaccine question likewise remains unresolved: researchers and health authorities are assessing candidates and possible cross-protection, not announcing a proven Bundibugyo-specific vaccine.
Sources
- Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda, World Health Organization
- WHO Technical Advisory Group on Candidate Vaccine Prioritization: meeting report, World Health Organization
- WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks, World Health Organization
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.